The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)
Background: Fluvoxamine (FVX) has been proposed as a potential treatment for severe COVID-19 by the σ-1 receptor agonist, which can reduce cytokine production. However, the efficacy of FVX remains controversial. Methods: A historical retrospective cohort study was conducted in mild to moderate COVID...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Elsevier,
2023-12-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |